Improving the Clinical Utility of Umbilical Cord Blood Donations by Ex-Vivo Expansion Using Mesenchymal Stromal Cells

本项目将评估通过与间充质基质细胞（MSCs）共培养介导的体外扩增来提高脐带血（UCB）临床应用的可行性。我们拥有生产多能干细胞衍生的MSC的专利技术，这意味着我们可以几乎无限量地提供这些细胞。在脐血中发现的造血干细胞和祖细胞具有巨大的临床价值，我们的MSC表现出比骨髓来源的MSC的几个优势。超过一半的UCB单位不能用于临床，因为它们缺乏足够数量的造血干细胞或祖细胞。这个可行性项目将建立在专利和其他先前的工作，并创造机会，建立一个具有重要临床影响的重大业务。

This project will assess the feasibility of improving the clinical utility of umbilical cord blood (UCB) through ex vivo expansion mediated by co-culture with mesenchymal stromal cells (MSCs). We have patented technology for the production pluripotent stem cell derived MSCs, which means that we can supply these cells in almost limitless quantities. The haematopoietic stem and progenitor cells found in UCB are of immense clinical value and our MSCs exhibit several advantages over bone marrow derived MSCs. Over half of all UCB units cannot be used clinically as they lack sufficient quantities of haematopoietic stem or progenitor cells. This feasibility project will build on patented and other prior work and create the opportunity to establish a significant business with important clinical impact.